

MECHANISMS OF VASCULAR DISEASE:

A REFERENCE BOOK FOR VASCULAR SPECIALISTS

27

An illustration of a cross-section of a blood vessel wall. The vessel lumen is on the left, and the vessel wall is on the right. The vessel wall is composed of a layer of endothelial cells (yellowish, flat cells) and a thicker layer of smooth muscle cells (reddish, fibrous). Several atherosclerotic plaques are shown as green, bumpy masses protruding from the endothelial surface. One plaque has an orange arrow pointing down towards it, and another has an orange arrow pointing up away from it. A large white number '27' is overlaid on the illustration.

EDITED BY ROBERT FITRIDGE AND MATTHEW THOMPSON
COMPLETELY UPDATED EDITION 2011

BARR SMITH PRESS

Mechanisms of Vascular Disease

Mechanisms of Vascular Disease:

A Reference Book for Vascular Specialists

Robert Fitridge

The University of Adelaide, The Queen Elizabeth Hospital, Woodville, Australia

Matthew Thompson

St George's Hospital Medical School, London, UK



BARR SMITH PRESS

An imprint of
The University of Adelaide Press

Published in Adelaide by

The University of Adelaide, Barr Smith Press
Barr Smith Library
The University of Adelaide
South Australia 5005
press@adelaide.edu.au
www.adelaide.edu.au/press

The University of Adelaide Press publishes peer-reviewed scholarly works by staff via Open Access online editions and print editions.

The Barr Smith Press is an imprint of the University of Adelaide Press, reserved for scholarly works which are not available in Open Access, as well as titles of interest to the University and its associates. The Barr Smith Press logo features a woodcut of the original Barr Smith Library entrance.

© The Contributors 2011

This book is copyright. Apart from any fair dealing for the purposes of private study, research, criticism or review as permitted under the Copyright Act, no part may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission. Address all inquiries to the Director at the above address.

This CIP cataloguing for this work is as follows;

Mechanisms of vascular disease : a reference book for vascular surgeons / Robert Fitridge, Matthew Thompson, [editors].

1. Blood vessels, Diseases.
2. Blood vessels, Surgery.

- I. Fitridge, Robert
- II. Thompson, M. M.

For the full Cataloguing-in-Publication data please contact National Library of Australia:
cip@nla.gov.au

ISBN (paperback) 978-0-9871718-2-5

Book design: Midland Typesetters

Cover design: Emma Spoehr, based on a diagram by Dave Heinrich of the Medical Illustration and Media Unit, Flinders Medical Centre

Paperback edition printed by Griffin Press, South Australia

Table of Contents

Contributors vii

Detailed Contents xi

1. Endothelium 1
Paul Kerr, Raymond Tam, Frances Plane (Calgary, Canada)
2. Vascular smooth muscle structure and function 13
David Wilson (Adelaide, Australia)
3. Atherosclerosis 25
Gillian Cockerill, Qingbo Xu (London, UK)
4. Mechanisms of plaque rupture 43
Ian Loftus (London, UK)
5. Current and emerging therapies in atheroprotection 79
Stephen Nicholls, Rishi Puri (Cleveland, USA)
6. Molecular approaches to revascularisation in peripheral vascular disease 103
Greg McMahon, Mark McCarthy (Leicester, UK)
7. Biology of restenosis and targets for intervention 115
Richard Kenagy (Seattle, USA)
8. Vascular arterial haemodynamics 153
Michael Lawrence-Brown, Kurt Liffman, James Semmens, Ilija Sutalo (Melbourne & Perth, Australia)
9. Physiological haemostasis 177
Simon McRae (Adelaide, Australia)
10. Hypercoagulable states 189
Simon McRae (Adelaide, Australia)
11. Platelets in the pathogenesis of vascular disease and their role as a therapeutic target 201
Sandeep Prabhu, Rahul Sharma, Karlheinz Peter (Melbourne, Australia)
12. Pathogenesis of aortic aneurysms 227
Jonathan Golledge, Guo-Ping Shi, Paul Norman (Townsville & Perth, Australia; Boston, USA)
13. Pharmacological treatment of aneurysms 247
Matthew Thompson, Janet Powell (London, UK)
14. Aortic dissection and connective tissue disorders 255
Mark Hamilton (Adelaide, Australia)
15. Biomarkers in vascular disease 277
Ian Nordon, Robert Hincliffe (London, UK)
16. Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon 295
Martin Veller (Johannesburg, South Africa)
17. SIRS, sepsis and multiorgan failure 315
Vishwanath Biradar, John Moran (Adelaide, Australia)
18. Pathophysiology of reperfusion injury 331
Prue Cowled, Robert Fitridge (Adelaide, Australia)
19. Compartment syndrome 351
Edward Choke, Robert Sayers, Matthew Bown (Leicester, UK)
20. Pathophysiology of pain 375
Stephan Schug, Helen Daly, Kathryn Stannard (Perth, Australia)

21. Postamputation pain 389
Stephan Schug, Gail Gillespie
(Perth, Australia)
 22. Treatment of neuropathic pain 401
Stephan Schug, Kathryn Stannard
(Perth, Australia)
 23. Principles of wound healing 423
Gregory Schultz, Gloria Chin,
Lyle Moldauer, Robert Diegelmann
(Florida, USA)
 24. Pathophysiology and principles of
varicose veins 451
Andrew Bradbury (Birmingham, UK)
 25. Chronic venous insufficiency and leg
ulceration: Principles and vascular
biology 459
Michael Stacey (Perth, Australia)
 26. Pathophysiology and principles of
management of the diabetic foot 475
David Armstrong, Timothy Fisher,
Brian Lepow, Matthew White,
Joseph Mills (Tucson, USA)
 27. Lymphoedema – Principles, genetics
and pathophysiology 497
Matt Waltham (London, UK)
 28. Graft materials past and future 511
Mital Desai, George Hamilton
(London, UK)
 29. Pathophysiology of vascular graft
infections 537
Mauro Vicaretti (Sydney, Australia)
- Index 549

List of Contributors

David G Armstrong
The University of Arizona
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Vishwanath Biradar
Intensive Care Unit
The Queen Elizabeth Hospital
Woodville, SA
Australia

Matthew Bown
Department of Vascular Surgery
University of Leicester
Leicester
UK

Andrew W Bradbury
University Department of Vascular Surgery
Birmingham Heartlands Hospital
Birmingham
UK

Edward Choke
Department of Vascular Surgery
University of Leicester
Leicester
UK

Gillian Cockerill
Department of Clinical Sciences
St George's Hospital Medical School
London
UK

Prue Cowled
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Helen Daly
Royal Perth Hospital
Perth, WA
Australia

Mital Desai
University Department of Vascular Surgery
Royal Free Hospital
University College
London
UK

Robert F Diegelmann
Department of Biochemistry
Medical College of Virginia
Richmond, VA
USA

Timothy K Fisher
Rashid Centre for Diabetes and Research
Sheikh Khalifa Hospital
Ajmon
UAE

Robert A Fitridge
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Gail Gillespie
Royal Perth Hospital
Perth, WA
Australia

Jonathan Golledge
Vascular Biology Unit
School of Medicine & Dentistry
James Cook University
Townsville, QLD
Australia

George Hamilton
University Department of Vascular Surgery
Royal Free Hospital
University College
London
UK

Mark Hamilton
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Robert J Hinchliffe
St George's Vascular Institute
St George's Hospital
London
UK

Richard D Kenagy
Department of Surgery
University of Washington
Seattle, WA
USA

Paul Kerr
Department of Pharmacology
University of Alberta
Alberta
Canada

Michael MD Lawrence-Brown
Curtin Health Innovation Research
Institute
Curtin University
Perth, WA
Australia

Brian Lepow
The University of Arizona
Department of Surgery
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Kurt Liffman
CSIRO Material Science & Engineering
and School of Mathematical Sciences
Monash University
Melbourne, Vic
Australia

Ian Loftus
Department of Vascular Surgery
St George's Hospital
London
UK

Mark J McCarthy
Department of Surgery and Cardiovascular
Sciences
University of Leicester
Leicester
UK

Greg S McMahon
Department of Surgery and Cardiovascular
Sciences
University of Leicester
Leicester
UK

Simon McRae
Adult Haemophilia Treatment Centre
SA Pathology
Adelaide, SA
Australia

Joseph L Mills
The University of Arizona
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Lyle Moldawer
Department of Surgery
University of Florida
Gainesville, FL
USA

John L Moran
Faculty of Health Sciences
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Stephen Nicholls
The Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH
USA

Ian M Nordon
St George's Vascular Institute
St George's Hospital
London
UK

Paul E Norman
School of Surgery
University of WA
Fremantle, WA
Australia

Karlheinz Peter
Baker IDI Heart & Diabetes Institute
Melbourne, Vic
Australia

Frances Plane
Department of Pharmacology
University of Alberta
Alberta
Canada

Janet T Powell
Imperial College
London
UK

Sandeep Prabhu
Baker IDI Heart & Diabetes Institute
Alfred Hospital
Melbourne, Vic
Australia

Rishi Puri
The Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH
USA

Stephan A Schug
Royal Perth Hospital
Perth, WA
Australia

Gregory S Schultz
Department of Obstetrics and Gynaecology
University of Florida
Gainesville, FL
USA

Rahul Sharma
Baker IDI Heart & Diabetes Institute
Alfred Hospital
Melbourne, Vic
Australia

Guo-Ping Shi
Department of Cardiovascular Medicine
Brigham & Women's Hospital
Harvard Medical School
Boston, MA
USA

Michael Stacey
University Department of Surgery
Fremantle Hospital
Fremantle, WA
Australia

Ilija D Sutalo
CSIRO Material Science & Engineering
and Curtin Health Innovation
Research Institute
Curtin University
Highett, Vic

Raymond Tam
Department of Pharmacology
University of Alberta
Alberta
Canada

Matthew Thompson
St Georges Hospital Medical School
London
UK

Martin Veller
Department of Surgery
University of Witwatersrand
Johannesburg
South Africa

Mauro Vicaretti
Department of Vascular Surgery
Westmead Hospital
Westmead, NSW
Australia

Matt Waltham
Academic Department of Surgery
St Thomas' Hospital
London
UK

Matthew L White
Vascular and Endovascular Surgery
University of Arizona
Tucson, AZ
USA

David P Wilson
School of Medical Sciences
Discipline of Physiology
University of Adelaide
Adelaide SA
Australia

Qingbo Xu
Department of Cardiology
Kings College
University of London
UK

Detailed Contents

CHAPTER 1 – ENDOTHELIUM

Paul Kerr, Raymond Tam, Frances Plane

- Introduction 1
- Endothelium-dependent regulation of vascular tone 2
- Angiogenesis 7
- Haemostasis 8
- Inflammation 9
- Conclusions 10
- References

CHAPTER 2 – VASCULAR SMOOTH MUSCLE STRUCTURE AND FUNCTION

David Wilson

- Introduction 13
- Smooth muscle (vascular) structure
- Cytoskeleton 14
- Contractile myofilament
- Functional regulation of vascular smooth muscle: Neuronal, hormonal, receptor mediated 15
- Smooth muscle function 17
- Myofilament basis of smooth muscle contraction and relaxation
- Smooth muscle contraction and relaxation 18
- Ion channels important in the regulation of smooth muscle function
- Regulation of cellular Ca^{2+}
- Sources of cytosolic Ca^{2+} entry 19
- Potassium channels
- Endothelial regulation of smooth muscle vasodilatation 20

Smooth muscle proliferation and vascular remodeling 20

Summary 22

References

CHAPTER 3 – ATHEROSCLEROSIS

Gillian Cockerill, Qingbo Xu

Introduction 25

Atherosclerotic lesions 26

Fatty streaks

Plaque or atheroma

Hypercholesterolemia and oxidised-LDL 27

High-density lipoproteins role in atheroprotection 28

Hypertension and biomechanical stress 29

Biomechanical stress-induced cell death 30

Biomechanical stress and inflammation 31

Biomechanical stress-induced smooth muscle cell proliferation 32

Infections and heat shock proteins

Infections

Heat shock proteins 33

Infections and HSP expression

Infections, sHSP and innate immunity 34

Immune responses 36

MHC class II antigens and T cells

Oxidised LDL as a candidate antigen

HSP60 as a candidate antigen 37

B2-glycoprotein Ib as a candidate antigen

Inflammation

C-reactive protein	38
CD40/CD40L	
Summary and perspectives	39
References	

CHAPTER 4 – MECHANISMS OF PLAQUE RUPTURE

Ian Loftus

Introduction	43
Evidence for the ‘plaque rupture theory’	44
Coronary circulation	
Cerebral circulation	
The role of individual components of the arterial wall	
The endothelium	45
The lipid core	47
The cap of the plaque	49
Smooth muscle cells and collagen production	50
Macrophages and collagen degradation	51
The vessel lumen	56
The role of angiogenesis in plaque rupture	
The role of infectious agents in plaque rupture	57
Risk prediction of plaque instability	58
Imaging	
Blood markers	59
Therapy aimed at plaque stabilisation	
HMG Co-A reductase inhibitors	60
MMP inhibition	
Tissue inhibitors of metalloproteinases (TIMPs)	61
Synthetic MMP inhibitors	
Doxycycline	
ACE inhibitors	
Summary	62
References	63

CHAPTER 5 – CURRENT AND EMERGING THERAPIES IN ATHEROPROTECTION

Stephen Nicholls, Rishi Puri

Background	79
Pathology	
Risk factor modification	80
Statins, LDL lowering and C-reactive protein	
The complexity of HDL	84
The controversy of triglycerides	87
Hypertension	
Risk factor modification in the diabetic patient	89
Glycaemic control	
Global risk factor reduction in diabetics	91
The metabolic syndrome	92
Future targets	93
Conclusion	
References	94

CHAPTER 6 – MOLECULAR APPROACHES TO REVASCULARISATION IN PERIPHERAL VASCULAR DISEASE

Greg S McMahon, Mark J McCarthy

Introduction	103
Mechanisms of vascular growth	
Vasculogenesis	
Angiogenesis	104
Neovessel maturation	105
Microvascular network maturation	106
Arteriogenesis	
Therapeutic induction of vascular growth	107
Delivery of molecular activators of vascular growth	
Angiogenic activators	108
Arteriogenic activators	109
Clinical trials for angiogenic therapy of peripheral vascular disease	
Conclusions	110
References	

CHAPTER 7 – BIOLOGY OF RESTENOSIS AND TARGETS FOR INTERVENTION

Richard Kenagy

Introduction 115

Mechanisms of restenosis

Thrombosis 116

Remodelling

Intimal hyperplasia 123

Sequence of events after injury

Origin of intimal cells 125

Inflammation 126

Role of ECM production 127

The contribution of specific factors to restenosis

Growth factors/cytokines

Inhibitors 128

Coagulation and fibrinolytic factors 129

Matrix metalloproteinases

Extracellular matrix/receptors

Targets for intervention 130

Intracellular signalling molecules

mTOR and microtubules

Transcription factors

miRNA 131

Inflammation targets

Brachytherapy

Extracellular targets and cell-based therapies

Angiotensin pathway

Cell-based therapies 132

Differential effects on endothelium and SMCs

Delivery devices

Prevention versus reversal of restenosis

Conclusions 133

References 134

CHAPTER 8 – VASCULAR ARTERIAL HAEMODYNAMICS

Michael Lawrence Brown, Kurt Liffman, James Semmens, Ilija Sutalo

Introduction 153

Laplace's law of wall of tension 154

Newtonian fluid 155

Non-Newtonian fluid

Poiseuille flow 158

Bernoulli's equation

Young's modulus and pulsatile flow 159

Mass conversion 161

Reynold's number

Arterial dissection, collateral circulation and competing flows 163

Shear stress and pressure 164

Forces on graft systems 165

Case 1 – The cylindrical graft 168

Case 2 – The windsock graft

Case 3 – The curved graft 169

Case 4 – The symmetric bifurcated graft

Computational modelling 170

Recent development and future directions 171

Conclusions 172

References 173

CHAPTER 9 – PHYSIOLOGICAL HAEMOSTASIS

Simon McRae

Introduction 177

Primary haemostasis

Platelets

Platelet adhesion

Platelet activation and shape change 179

Platelet aggregation 180

Interactions between primary and secondary haemostasis 181

Secondary haemostasis

The coagulation cascade 182

Initiation 183

Amplification

Propagation 184

Normal inhibitors of coagulation

Fibrinolysis 185

Conclusions 186

References

CHAPTER 10 – HYPERCOAGULABLE STATES

Simon McRae

Introduction 189

Classification of thrombophilia

Inherited thrombophilia 190

Type 1 conditions

Antithrombin deficiency

Protein C and Protein S deficiency

Type 2 conditions 191

Factor V Leiden

The prothrombin (G20210A) gene mutation

FVL/PGM compound heterozygotes

Other inherited conditions

Acquired thrombophilia 192

Antiphospholipid antibodies

Heparin induced thrombocytopenia

Myeloproliferative disorders 193

Potential reasons for performing thrombophilia testing

Patients with venous thrombosis and their relatives

Providing an understanding of the aetiology of a thrombotic event

Determining risk of recurrence and therefore optimal duration of anticoagulation 194

Determining the need for primary prophylaxis in asymptomatic family members 195

Making decisions regarding the use of the oral contraceptive pill 196

Determining the need for thromboprophylaxis during pregnancy

Patients with arterial thrombosis

Potential detrimental effects of thrombophilia testing 197

Conclusion

References

CHAPTER 11 – PLATELETS IN THE PATHOGENESIS OF

VASCULAR DISEASE AND THEIR ROLE AS A THERAPEUTIC TARGET

*Sandeep Prabhu, Rahul Sharma,
Karlheinz Peter*

Introduction 201

Platelet function – Adhesion and activation

Platelet adhesion 202

Platelet activation 203

Mediators of platelet activation and ‘outside in’ signalling

Thrombin and collagen 204

Adenosine diphosphate (ADP)

Thromboxane A2 (TXA2)

Adrenaline 206

Second messenger systems 207

Physiological consequences of platelet activation

The GP IIb/IIIa receptor and ‘inside-out’ signalling

Granule exocytosis 208

Activation-induced conformational change of platelets

Platelets and atherosclerosis 209

Role of platelets in the initiation of the atherosclerosis

Role of the platelets in the progression of the atherosclerosis

Role of platelets in vulnerable plaques and plaque rupture

Current and future anti-platelet agents 210

Aspirin (salicylic acid)

Thienopyridines 211

Clopidogrel

Prasugrel 213

Ticlopidine

Ticagrelor

GPIIb/IIIa Antagonists

Other anti-platelet agents and promising new developments 214

Platelet function testing 215

Light-transmission aggregometry

Whole blood aggregometry 217
 VerifyNow® Assay
 Flow cytometry 218

References

CHAPTER 12 – PATHOGENESIS OF AORTIC ANEURYSMS

*Jonathan Golledge, Guo-Ping Shi,
 Paul E Norman*

Introduction 227

Differences between thoracic and abdominal aortic aneurysms 228

Summary of current theories and stages of AAA evolution

Atherosclerosis and AAA

Immune mechanisms in AAA 229

Extracellular matrix dysfunction 232

Infection 233

Biomechanical forces

Angiogenesis

Intra-luminal thrombus

Extracellular matrix proteolysis 234

Genetics 236

AAA rupture 237

Biomechanical factors in aneurysms rupture

The role of enzymes in AAA rupture

Role of intraluminal thrombus in aneurysm rupture 238

Future research

References

CHAPTER 13 – PHARMACOLOGICAL TREATMENT OF ANEURYSMS

Matthew Thompson, Janet T Powell

Background 247

Screening programmes

Pathophysiology 248

Therapeutic strategies

Beta blockade

Modification of the inflammatory

response 249

Non-steroidal anti-inflammatories

Matrix metalloproteinase (MMP)

inhibition

Anti-chlamydial therapy 250

Drugs acting on the renin/angiotensin axis

HMG Co-A reductase inhibitors 251

The future – Data from recent

experimental studies

References

CHAPTER 14 – PATHOPHYSIOLOGY OF AORTIC DISSECTION AND CONNECTIVE TISSUE DISORDERS

Mark Hamilton

Introduction 255

Embryology of thoracic aorta and arch vessels

Haemodynamics of thoracic compared to abdominal aorta 257

Sizes of normal aorta

Classification of aortic syndromes

Acute/Chronic

DeBakey classification of class 1 dissection – Type 1, 2, and 3

Stanford classification 258

European task force

Pathogenesis of thoracic aortic dissection

Classical thoracic aortic dissection (class 1 dissection) 260

Intramural haematoma (class 2 aortic dissection) 261

Penetrating aortic ulcer (class 4 aortic dissection) 262

Complications of acute aortic syndromes 263

Visceral ischaemia /malperfusion syndromes

Fate of the false lumen

Aneurysmal degeneration and rupture 264

Connective tissue disorders and acute aortic syndromes

Marfan syndrome	
Fibrillin and Marfan syndrome	265
The role of transforming growth factor beta in development of the vascular system in health and disease	266
Ehlers-Danlos syndrome	267
Diagnosis of Ehlers-Danlos syndrome	268
Loeys-Deitz syndrome	270
Familial thoracic aortic aneurysm disease	271
Bicuspid aortic valve	273
Turners Syndrome	
Summary	274
Reference list	

CHAPTER 15 – BIOMARKERS IN VASCULAR DISEASE

Ian M Nordon, Robert J Hinchliffe

Introduction	277
What is a biomarker?	
Types of biomarkers	
A classical clinical example	278
Potential value of biomarkers in vascular disease	279
Biomarker discovery steps	280
AAA biomarkers	
Circulating extracellular matrix markers	281
Matrix-degrading enzymes	283
Proteins associated with thrombosis	
Markers of inflammation	284
Biomarkers of AAA rupture	285
Biomarkers following endovascular repair	
Inflammation	287
Lipid accumulation	
Apoptosis	
Thrombosis	
Proteolysis	288
Challenges in biomarkers discovery	
Future work	
Conclusion	289
References	

CHAPTER 16 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VASCULITIS AND RAYNAUD'S PHENOMENON

Martin Veller

Vasculitides	295
Introduction	
Classification of vasculitides	296
Clinical presentation of vasculitides	
Investigations of vasculitides	
Principles of treatment of vasculitides	297
The vasculitides of specific interest to vascular surgeons	298
Giant cell arteritis	
Takayasu's arteritis	299
Thromboangitis obliterans (Buerger's disease)	300
Behcet's disease	301
Polyarteritis nodosa	302
Vasculitides secondary to connective tissue diseases	303
Systemic lupus erythematosus (SLE)	
Antiphospholipid antibody syndrome (APS)	304
Rheumatoid arthritis	305
Scleroderma	
Infective vasculitides	306
Human immunodeficiency virus (HIV)	
Pathophysiology and principles of Raynaud's phenomenon	307
Prevalence of Raynaud's phenomenon	308
Clinical findings in Raynaud's phenomenon	309
Diagnosis of Raynaud's phenomenon	
Prognosis	310
Treatment	
Recommendations	311
References	312

CHAPTER 17 – SIRS, SEPSIS AND

MULTIORGAN FAILURE*Vishwanath Biradar, John Moran***Epidemiology 315****Historical perspectives and definition 316****Risk factors for sepsis 317**

Causative agents

Pathophysiology of sepsis

innate immunity and toll-like receptors (TLRs) 319

Proinflammatory response

Coagulation cascade

Multorgan dysfunction syndrome (MODS) 320

Epithelial and endothelial dysfunction

Immune suppression and apoptosis

Sepsis, circulatory failure and organ dysfunction

Management 322

Steroids 323

Recombinant human activated protein C (rhAPC) 324

Glucose control 325

Renal replacement therapy

3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors (HMG-CoA) 326

Other adjuvant therapies in sepsis

Cytokines and anticytokine therapies

Pooled immunoglobulin (IVIG)

Acute respiratory distress syndrome (ARDS) 327

References**CHAPTER 18 –
PATHOPHYSIOLOGY OF
REPERFUSION INJURY***Prue Cowled, Rob Fitridge***Introduction 331****Ischaemia**

ATP and mitochondrial function

Gene expression during ischaemia 332

Reperfusion 333

Reactive oxygen species

Eicosanoids 334

Nitric Oxide 335

Endothelin 336

Cytokines

Neutrophil and endothelial interactions 338

Complement activation 340

Tissue destruction 341

Proteases and metalloproteinases

Apoptotic cell death during ischaemia-reperfusion injury

No-reflow phenomenon 342

Therapeutic approaches to IRI

Ischaemic preconditioning

Ischaemic post-conditioning 343

Conditioning effects of volatile anaesthetics

Pharmacological treatments 344

Summary 345**References****CHAPTER 19 – COMPARTMENT
SYNDROME***Edward Choke, Robert Sayers, Matthew Bown***Definition 351****Acute limb compartment syndrome**

Incidence

Anatomy/physiology 352

Aetiology/pathophysiology

Clinical presentation 354

Investigation 355

Treatment 357

Complication of LCS 359

Outcome 360

Acute abdominal compartment syndrome

Incidence 361

Aetiology

Pathological effects of raised intra-abdominal pressure 362

Clinical presentation 363

Investigation

Treatment 364

Complications of surgical decompression

Outcome 367

References 368

CHAPTER 20 – PATHOPHYSIOLOGY OF PAIN

Stephan Schug, Helen Daly, Kathryn Stannard

Introduction 375

Peripheral mechanisms

Nociception/transduction

Conduction 376

Spinal cord mechanisms

Ascending systems 377

Descending control

Pain modulation 378

Peripheral sensation

Central sensitisation in the dorsal horn

Neuropathic pain 379

Mechanisms of neuropathic pain

Peripheral mechanisms

Spontaneous ectopic discharge

Altered gene expression

Spared sensory neurons

Involvement of the sympathetic nervous system 380

Collateral sprouting

Effects of bradykinin

Central mechanisms

Wind up

Central sensitization 381

Central disinhibition

Expansion in receptive field size (recruitment)

Immediate early gene expression

Anatomical re-organisation of the spinal cord

Contribution of glial cells to pain conditions 382

Symptoms of neuropathic pain

Stimulus-dependent pain

Stimulus-independent pain 383

Sympathetically maintained pain (SMP)

Neuropathic pain syndromes

Peripheral neuropathies

Central neuropathies 385

References

CHAPTER 21 – POST-AMPUTATION PAIN

Stephan Schug, Gail Gillespie

Introduction 389

Classification and incidence of post-amputation pain syndromes

Stump pain

Phantom sensation 390

Phantom limb pain

Pathophysiology of post-amputation pain syndromes

Peripheral factors

Spinal factors 391

Supraspinal factors

Current pathophysiological model of post-amputation pain syndromes 392

Prevention of post-amputation pain

Perioperative lumbar epidural blockade

Peripheral nerve blockade 393

NMDA antagonists

Evaluation of the patient with post-amputation pain syndromes

Examination

Therapy of post-amputation pain syndromes 394

Calcitonin

Ketamine

Analgesic and Co-analgesic compounds

Opioids 395

Gabapentin

Clonazepam

Lidocaine

Carbamazepine

Tricyclic antidepressants (TCA)

Selective serotonin reuptake inhibitors

Baclofen

Capsaicin

Symptomatic treatment of pain components 396

Neuropharmacological therapies

Invasive therapies
 Electroconvulsive therapy (ECT)
 Nerve blockade
 Spinal cord stimulation
 Implantable intrathecal delivery systems
 Dorsal root entry zone (DREZ) lesions
 Psychological therapy 397

Future aims

References

CHAPTER 22 – TREATMENT OF NEUROPATHIC PAIN

Stephan Schug, Kathryn Stannard

Introduction 401

Principles of treatment

Pharmacological treatment 402

Opioids

Recommendations for clinical use of opioids

Tramadol

Mechanism of action

Efficacy 403

Adverse effects

Recommendations for clinical use of tramadol in neuropathic pain

Antidepressants

Tricyclic antidepressants (TCAs)

Mechanism of action 404

Adverse effects

Selective serotonin re-uptake inhibitors (SSRIs)

Serotonin/Noradrenaline reuptake inhibitors (SNRIs) 405

Recommendations for clinical use of antidepressants as analgesics

Anticonvulsants

Mechanism of action 406

Individual medications

Clonazepam

Gabapentin

Pregabalin 407

Carbamazepine

Sodium valproate 408

Phenytoin

Lamotrigene

Recommendations for clinical use of anticonvulsants as analgesics

Local anaesthetics and antiarrhythmics 409

Mechanism of action

Lignocaine

Mexiletine

Recommendations for clinical use of lignocaine and mexiletine in neuropathic pain

N-methyl-D-aspartate-receptor antagonists (NMDA)

Ketamine 410

Other NMDA antagonists

Miscellaneous compounds for systemic use

Clonidine

Efficacy

Baclofen

Levodopa 411

Cannabinoids

Topical treatments

Lignocaine 5% medicated plaster

Capsaicin 412

Mechanism of action

Efficacy

Non-pharmacological therapy

Transcutaneous electrical nerve stimulation (TENS)

Spinal cord stimulation (SCS) 413

Sympathetic nerve blocks

Neurosurgical destructive techniques

Cognitive behaviour therapy

References 414

CHAPTER 23 – PRINCIPLES OF WOUND HEALING

Gregory Schultz, Gloria Chin, Lyle Moldawer, Robert Diegelmann

Introduction 423

Phases of acute wound healing

Haemostasis

- Inflammation 426
 - Neutrophils 427
 - Macrophages 428
- Proliferative phase 429
 - Fibroblast migration 430
 - Collagen and extracellular matrix production
 - Angiogenesis 431
 - Granulation 432
 - Epithelialization
 - Remodelling 433
- Summary of acute wound healing 435
- Comparison of acute and chronic wounds**
 - Normal and pathological responses to injury
 - Biochemical differences in the molecular environments of healing and chronic wounds 436
 - Biological differences in the response of chronic wound cells to growth factors 439
- From bench to bedside**
 - Role of endocrine hormones in the regulation of wound healing
 - Molecular basis of chronic non-healing wounds
 - Chronic venous stasis ulcers 441
 - Pressure ulcers
- Future concepts for the treatment of chronic wounds 442**
 - Bacterial biofilms in chronic wounds 443
- Conclusion 445**
- References**

CHAPTER 24 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VARICOSE VEINS

Andrew Bradbury

- Introduction 451**
- Anatomy**
- Histology 452**
- Physiology**

- Varicose veins 453**
- Valvular abnormalities**
- Muscle pump failure 455**
- Venous recirculation**
- Recurrent varicose veins**
 - New varicose veins
 - Persistent varicose veins
 - True recurrent varicose veins 456
- Cellular and molecular biology of varicose veins**
- Conclusion 457**
- References**

CHAPTER 25 – CHRONIC VENOUS INSUFFICIENCY AND LEG ULCERATION: PRINCIPLES AND VASCULAR BIOLOGY

Michael Stacey

- Definitions 459**
 - Chronic venous insufficiency
 - Leg ulceration
 - Assessment of cause of leg ulceration 460
- Epidemiology 461
- Pathophysiology
 - Venous abnormality
 - Effect of ambulatory venous hypertension on the tissues in the leg 463
 - Influence of venous disease on the wound healing process 465
 - Genetic associations with venous ulceration 466
- Assessment of venous function 467**
- Treatment of venous ulceration**
 - Compression therapy
 - Dressings 468
 - Surgery
 - Prevention of venous ulcer recurrence 470
 - Sclerotherapy and other techniques to obliterate surface and perforating veins
 - Other therapies 471
- References**

CHAPTER 26 –
PATHOPHYSIOLOGY AND
PRINCIPLES OF MANAGEMENT
OF THE DIABETIC FOOT

*David Armstrong, Timothy Fisher, Brian
Lepow, Matthew White, Joseph Mills*

- Introduction** 475
- Pathophysiology of the diabetic foot** 476
- Neuropathy
 - Structural abnormalities/gait abnormalities
 - Angiopathy 478
- Diagnosis**
- History and rapid visual screening
 - Neurological examination 479
 - Monofilament testing
 - Vibration testing
 - Dermatologic examination 480
 - Anatomy of occlusive disease – vascular examination
 - Prediction of wound healing: assessment of perfusion 481
 - Arterial imaging
 - Soft tissue imaging 482
- Classification systems** 483
- Diabetes mellitus foot risk classification
 - University of Texas wound classification system
- Clinical problems and principles of management** 484
- Ulceration
 - Epidemiology and risk factors
 - Offloading
 - Non-vascular surgical treatment 485
 - Class I – Elective 486
 - Class II – Prophylactic
 - Class III – Curative
 - Class IV – Emergency (urgent)
 - Post-operative management
 - Infections 487
 - Charcot arthropathy
- Prevention** 490
- Conclusion** 492
- References**

CHAPTER 27 – LYMPHOEDEMA
– PRINCIPLES, GENETICS AND
PATHOPHYSIOLOGY

Matt Waltham

- Introduction** 497
- Classification of lymphoedema**
- Classification of primary lymphoedema 498
- The genetics of lymphangiogenesis in primary lymphoedema** 500
- Milroy's disease
 - Lymphoedema – distichiasis syndrome 501
 - Hypotrichosis – lymphoedema – telangiectasia syndrome 502
 - Meige disease (primary non-syndromic lymphoedema)
 - Other primary lymphoedema disorders 503
- Structure and development of the lymphatic circulation**
- Clinical aspects of lymphoedema** 505
- Summary**
- References**

CHAPTER 28 – GRAFT
MATERIALS PAST AND FUTURE

Mital Desai, George Hamilton

- The pathophysiology of graft healing** 511
- The peri-anastomotic area
 - Healing of prosthetic grafts 512
 - The healing process of the anastomosis
 - Graft porosity and permeability
- Physical properties of prosthetic materials** 514
- Tubular compliance
 - Anastomotic compliance mismatch
 - The compliance hypothesis of graft failure
- Synthetic grafts** 515
- Newer developments of Dacron grafts
 - Modifications and newer developments of PTFE grafts 517
 - Polyurethane grafts

Newer developments of polyurethane vascular grafts	518
Biological vascular grafts	519
Newer developments of biological vascular grafts	520
Prosthetic graft modifications	
Modifications to reduce graft infection	
Modifications to improve patency	521
Nanocomposite grafts	
Endothelial cell seeding	522
Single stage seeding	
Two stage seeding	
Vascular tissue engineering	
Non-degradable polymer and cell seeding	523
Bioresorbable and biodegradable polymers	
Combined bioresorbable and tissue engineered grafts	524
Mechanical conditioning of seeded vascular cells	
Alternative scaffolds	
Tissue-engineered grafts	525
Graft materials for aortic endografts	526
The future	
References	527

CHAPTER 29 – PATHOPHYSIOLOGY OF VASCULAR GRAFT INFECTIONS

Mauro Vicaretti

Introduction	537
Natural history of prosthetic vascular graft infections	
Mechanism of graft contamination at operation	538
Pathogenesis of graft infections	
Bacteriology of vascular graft infections	
Investigations for detection of prosthetic graft infections	539
History and physical examination	
Laboratory investigations	
Diagnostic imaging	540
Management of prosthetic graft infections	
Prevention	
Reduction of prosthetic vascular graft infection with rifampicin bonded gelatin sealed Dacron	541
Established infection	
Antibiotic therapy	
Operative management	
Conclusion	542
References	

Acknowledgements

The Editors gratefully acknowledge the outstanding contributions of each Author involved in this reference book. We would also like to acknowledge the invaluable efforts of Ms Sheona Page who has worked tirelessly on this project. We would also like to thank Prue Cowled PhD and Ms Cayley Wright for their assistance.

Abbreviation List

a1-PI	a1-protease inhibitor
5-HT	5-Hydroxytryptamine/Serotonin
AAA	Abdominal aortic aneurysm
AAS	Acute aortic syndrome
AAV	Adeno-associated viruses
ACE	Angiotensin converting enzyme
ACS	Acute coronary syndrome
ACS	Abdominal compartment syndrome
ACTH	Adrenocorticotrophic hormone
ADAMTS	A disintegrin and metalloproteinase with thrombospondin motifs
ADP	Adenosine diphosphate
AIDS	Acquired immune deficiency syndrome
ALI	Acute lung injury
AMP	Adenosine monophosphate
AMPA	α -amino-3 hydroxy-5-methylisoxazole
ANA	Anti-nuclear antibody
ANCA	Anti-neutrophil cytoplasmic antibody
AOD	Aortic occlusive disease
AP1	Activated protein 1
APC	Activated protein C
APC	Antigen presenting cell
APLAS	Antiphospholipid antibody syndrome
ApoAI	Apolipoprotein AI
ApoE	Apolipoprotein E
APS	Antiphospholipid antibody syndrome
APTT	Activated partial thromboplastin time

ARDS	Acute respiratory distress syndrome
AT	Antithrombin
ATP	Adenosine triphosphate
AVP	Ambulatory venous thrombosis
β 2-GPI	β 2-glycoprotein Ib
bFGF	Basic fibroblast growth factor
BKCa	Large conductance calcium activated potassium channel
BMPs	Bone morphogenetic proteins
BMS	Bare metal stent
CAD	Coronary artery disease
CaM	Calmodulin
CAM	Cell adhesion molecule
cAMP	Cyclic adenosine monophosphate
CCK	Cholecystokinin
cGMP	Cyclic guanine monophosphate
CD	Cluster of differentiation
CD40L	Cluster of differentiation 40 ligand
CEA	Carotid endarterectomy
CETP	Cholesteryl ester transfer protein
CFD	Computational fluid dynamics
CG	Cationized gelatin
CGRP	Calcitonin gene regulated peptide
CHD	Coronary heart disease
CI	Confidence interval
CIMT	Carotid intimal-media thickness
c-JNK	c-Jun N-terminal kinase
CK-MB	Creatinine kinase (Myocardial specific)
CNCP	Chronic noncancer pain
cNOS	Constitutive nitric oxygen synthase enzyme
COX-1	Cyclooxygenase-1
COX-2	Cyclooxygenase-2
CROW	Charcot restraint orthotic walker
CRRT	Continuous renal replacement therapy

CRP	C-reactive protein
CRPS	Complex regional pain syndromes
CT	Computational tomography
CTA	Computed tomographic angiography
CTD	Connective tissue disorders
CTGF	Connective tissue growth factor
CYP	Cytochrome P450
CVD	Cardiovascular disease
CVI	Chronic venous insufficiency
DAG	Diacylglycerol
DES	Drug-eluting stent
DRG	Dorsal root ganglion
DNA	Deoxyribonucleic acid
DSA	Digital subtraction arteriography
DTS	Dense tubular system
DVT	Deep vein thrombosis
EC	Endothelial cell
ECM	Extracellular matrix
EDCF	Endothelium-derived contracting factor
EDH	Endothelium-dependent hyperpolarisation
EDS	Ehlers-Danlos syndrome
EET	Epoxyeicosatrienoic acids
ELAM-1	Endothelial-leukocyte adhesion molecule-1
ELG	Endoluminal grafts
ELISA	Enzyme linked immunosorbent assay
E_K	Equilibrium potential
E_M	Membrane potential
eNOS	Endothelial nitric oxide synthase enzyme
EPC	Endothelial progenitor cells
EPCR	Endothelial protein C receptor
ePTFE	Expanded polytetrafluoroethylene
ERK	Extracellular signal-regulated kinase
ESR	Erythrocyte sedimentation rate

ET	Essential thrombocytosis
ET-1	Endothelin 1
EVAR	Endovascular aortic aneurysm repair
EVLA	Endovenous LASER ablation
FDA	Food and drug administration
FDPs	Fibrin degradation products (soluble)
FGF	Fibroblast growth factor
FGF-2	Fibroblast growth factor 2
FMN	Flavin mononucleotide
FVL	Factor V Leiden
GABA	Gamma-aminobutyric acid
GABA B	Gamma-aminobutyric acid subtype B
G-CSF	Granulocyte colony stimulating factor
GMCSF	Granulocyte-macrophage colony stimulating factor
GP	Glycoprotein
GPCR	G-protein coupled receptor
GSV	Great saphenous vein
HDL	High density lipoprotein
HDL-C	High density lipoprotein cholesterol
HIF	Hypoxia inducible factor
HIT	Heparin induced thrombocytopenia
HIV	Human immunodeficiency virus
HLA	Human leukocyte antigen
HMG Co-A	Hydroxymethylglutaryl coenzyme-A
HMW	High molecular weight
HPETE	Hydroperoxyeicosatetraenoic acid
HETE	Hydroxyeicosatetraenoic acids
HR	Hazard ratio
hsCRP	High-sensitive C-reactive protein
HSP	Heat shock protein
HUV	Human umbilical vein
IAH	Intra-abdominal hypertension

IAP	Intra-abdominal pressure
IAPP	Intra-abdominal perfusion pressure
ICAM-1	Inter-cellular adhesion molecule-1
ICAM-2	Inter-cellular adhesion molecule-2
ICP	Intra-compartmental pressure
ICU	Intensive care unit
IFN	Interferon
IGF-1	Insulin-like growth factor-1
IHD	Ischemic heart disease
IL	Interleukin
IL-1	Interleukin-1
IL-1 α	Interleukin-1 alpha
IL-1 β	Interleukin-1 beta
IL-6	Interleukin-6
IL-8	Interleukin-8
ILT	Intraluminal thrombus
IKCa	Intermediate conductance calcium-activated potassium channels
IMH	Intramural haematoma
IMP	Inosine monophosphate
iNOS	Inducible nitric oxide synthase enzyme
IP(3)	1,4,5-inositol triphosphate
IRI	Ischemia reperfusion injury
IVIG	Intravenous pooled immunoglobulin
IVUS	Intravascular ultrasound
KGF	Keratinocyte growth factor
KGF-2	Keratinocyte growth factor-2
LAP	Latency associated peptide
LCS	Limb compartment syndrome
LDL	Low density lipoprotein
LDS	Loeys-Dietz syndrome
LLC	Large latent complex
LEC	Lymphatic endothelial cells

LFA-1	Lymphocyte function-associated antigen-1
LO	Lipoxygenase
LOX	Lysyl oxidase
LOPS	Loss of protective sensation
LPA	Lysophosphatidic acid
LPS	Lipopolysaccharide
LTA	Lipoteichoic acid
LTGFBP	Latent TGF binding protein
MAC-1	Macrophage-1 antigen
MAPK	Mitogen activated protein kinase
MCP-1	Monocyte chemoattractant protein-1
M-CSF	Macrophage-colony stimulating factor
MFS	Marfan syndrome
MHC	Major histocompatibility
MI	Myocardial infarction
MIP-1	Macrophage inflammatory protein-1
MLC ₂₀	Myosin light chain ₂₀
MLCK	Myosin light chain kinase
MLCP	Myosin light chain phosphatase
MMP	Matrix metalloproteinase
MODS	Multiple organ dysfunction syndrome
MRA	Magnetic resonance angiography
MRI	Magnetic resonance imaging
mRNA	Messenger RNA
MRSA	Methicillin resistant <i>Staphylococcus aureus</i>
MRSE	Methicillin resistant <i>Staphylococcus epidermidis</i>
MRTA	Magnetic resonance tomographic angiography
MTHFR	Methylenetetrahydrofolate reductase
MT-MMP	Membrane-type MMP
MVPS	Mitral valve prolapse syndrome
NADPH	Nicotinamide adenine dinucleotide phosphate
NGF	Nerve growth factor

NFκB	Nuclear factor kappa B
NiTi	Nitinol
NJP	Non-junctional perforators
NMDA	N-methyl-D-aspartate
NNH	Number needed to harm
NNT	Number needed to treat
NO	Nitric oxide
NOS	Nitric oxide synthase enzyme
NSAID	Non-steroidal anti-inflammatory drug
NV	Neovascularisation
OCP	Oestrogen/progesterone contraceptive pill
OPN	Osteopontin
OPG	Osteoprotegerin
OR	Odds ratio
OxLDL	Oxidised low density lipoprotein
PAD	Peripheral arterial disease
PAF	Platelet activating factor
PAI	Plasminogen activator inhibitor
PAI-1	Plasminogen activator inhibitor-1
PAR	Protease activated receptor
PAR-1	Protease activated receptor-1
PAR-4	Protease activated receptor-4
PAU	Penetrating aortic ulcer
PC	Protein C
PCA	Poly (carbonate-urea) urethane
PCI	Percutaneous coronary intervention (angioplasty)
PCWP	Pulmonary capillary wedge pressure
PDGF	Platelet-derived growth factor
PDGFβ	Platelet-derived growth factor-β
PDS	Polydioxanone
PECAM-1	Platelet-endothelial cell adhesion molecule-1
PEDF	Pigment epithelium-derived factor
PES	Paclitaxel-eluting stent

PET	Positron emission tomography
PF4	Platelet factor 4
PGI ₂	Prostacyclin
PGG ₂	Prostaglandin G ₂
PGH ₂	Prostaglandin H ₂
PGEI ₂ /PGI ₂	Prostaglandin I ₂
PGN	Peptidoglycan
PHN	Postherpetic neuropathy
PHZ	Para-anastomotic hyper-compliant zone
PI3K	Phosphatidylinositol 3-kinase
PIP2	Phosphatidylinositol 4,5-bisphosphate
PLC	Phospholipase C
PLOD	Procollagen lysyl hydroxylase
PMCA	Plasma membrane Ca ²⁺ APTases
PMN	Polymorphonuclear leukocyte
POSS	Polyhedral oligomeric silsesquioxanes
PPAR	Peroxisomal proliferation activating receptor
PPI	Proton pump inhibitor
PRV	Polycythaemia rubra vera
PS	Protein S
PSGL-1	P-selectin glycoprotein ligand-1
PT	Prothombin time
PTCA	Percutaneous coronary angioplasty
PTFE	Polytetrafluoroethylene
PTS	Post-thrombotic syndrome
PUFA	Polyunsaturated fatty acid
PVI	Primary valvular incompetence
rAAA	Ruptured AAA
Rac	Ras activated cell adhesion molecule
RANTES	Regulated upon activation, normal T cell expressed and secreted
RAS	Renin angiotensin system
RCT	Randomised controlled trial

RF	Rheumatoid factor
RFA	Radiofrequency ablation
rhAPC	Recombinant human activated protein C
RNA	Ribonucleic acid
ROS	Reactive oxygen species
RR	Relative risk
RSD	Reflex sympathetic dystrophy
S1P	Sphingosine-1-phosphate
SAPK	Stress-activated protein kinase
SCF	Stem cell factor
SCS	Spinal cord stimulation
ScvO2	Superior vena cava venous oxygen saturation
SDF-1	Stromal-cell-derived factor-1
SERCA	Sarco/endoplasmic reticulum CaATPases
SEP	Serum elastin peptides
SES	Sirolimus-eluting stent
SEPS	Subfascial endoscopic perforator surgery
SFA	Superficial femoral artery
SFJ	Sapheno-femoral junction
SIRS	Systemic inflammatory response syndrome
SKCa	Small conductance calcium-activated potassium channels
SLE	Systemic lupus erythematosus
SMA	Smooth muscle alpha actin
SMC	Smooth muscle cell
SMP	Sympathetically maintained pain
SNARE	Soluble N-ethylmaleimide-sensitive factor activating protein receptors
SNP	Single nucleotide polymorphisms
SNRI	Serotonin/Noradrenaline reuptake inhibitors
SPJ	Sapheno-popliteal junction
SPP	Skin perfusion pressure
SR	Sarcoplasmic reticulum
SSRIs	Selective serotonin re-uptake inhibitors
SSV	Small saphenous vein

SVT	Superficial thrombophlebitis
STIM1	Stromal interacting molecule 1
T α CE	TNF α converting enzyme
TAAD	Thoracic aortic aneurysm disease
TAD	Thoracic aortic dissection
TAFI	Thrombin-activatable fibrinolysis inhibitor
Tc-99 MDP	Technetium-99 methylene diphosphonate
TCA	Tricyclic antidepressant
TCC	Total contact cast
TCR	T-cell receptor
TENS	Transcutaneous electrical nerve stimulation
TF	Tissue factor
TFPI	Tissue factor pathway inhibitor
TGF	Transforming growth factor
TGF- α	Transforming growth factor-alpha
TGF- β	Transforming growth factor-beta
TGL	Triglycerides
Th	T helper
TIA	Transient ischemic attack
TIMP	Tissue inhibitors of metalloproteinase
TLR	Toll-like receptors
TNF	Tumour necrosis factor
TNF- α	Tumour necrosis factor-alpha
tPA	Tissue-type plasminogen activator
TRP	Transient receptor potential
TRPC	Transmembrane receptor potential canonical
TRPV1	Transmembrane receptor potential Vanilloid-type
TXA2	Thromboxane A2
uPA	Urokinase
UT	University of Texas
VCAM	Vascular cell adhesion molecule
VCAM-1	Vascular cell adhesion molecule-1
VEGF	Vascular endothelial growth factor

VEGF-R	Vascular endothelial growth factor receptor
VIP	Vasoactive intestinal peptide
VLA-1	Very late activating antigen-1
VOCC	Voltage operated calcium channels
VPT	Vibratory perception threshold
VSMC	Vascular smooth muscle cells
VTE	Venous thromboembolism
VV	Varicose veins
vWF	von Willebrand factor
XO	Xanthine oxidase

27 • Lymphoedema – Principles, Genetics and Pathophysiology

MATT WALTHAM

Academic Department of Surgery, St Thomas' Hospital,
Westminster Bridge Road, London

INTRODUCTION

The lymphatic circulation consists of a network of blind-ended capillaries lined with endothelial cells that drain into larger vascular trunks and eventually empty into the blood circulation. It is otherwise totally separate from the blood circulation although lymphatics are often anatomically related to arteries and veins. Lymphatic vessels are found in nearly all tissues and have several important functions including transportation of fluids, plasma macromolecules, and cells back to the blood circulation. The lymphatics also form a major transport route for lipids absorbed from the intestinal tract, and are a critical component of the immune system transporting leucocytes and antigens from the tissues to the lymphoid organs.

Lymphoedema is an accumulation of tissue fluid in the interstitial space as a result of failure of the lymphatic circulation. This can be severe and disfiguring. Defects in the lymphatic system can be primary or acquired. Lymphoedema most frequently affects the legs (80%) although can present as swelling of the arms, face or external genitalia. (Figure 27.1)

CLASSIFICATION OF LYMPHOEDEMA

The diagnosis of lymphoedema should be reserved for those patients in whom a secondary cause of oedematous swelling has been excluded. (Table 27.1). Chronic venous disease is a common cause of unilateral swelling and there are often other characteristic skin changes. Sub-clinical lymphoedema sometimes becomes apparent when other conditions such as venous hypertension cause an increase in fluid and protein forced into the interstitial space that overwhelms a poorly functioning lymphatic system.

Lymphoedema is classified as primary when there is an intrinsic defect in the lymphatic vessels or nodes that leads to failure to drain lymph from the tissues. It has an incidence of 1:6000 and is three times more common in women than men.¹

Secondary lymphoedema is more common and occurs when the lymphatics are damaged by a defined external cause. The commonest cause worldwide with approximately 120 million cases is filarial infection (*Wuchereria bancrofti*, *Brugia malayi*



FIGURE 27.1 (a,b): Lower limb lymphoedema

or *Brugia timori*) leading to inflammation and fibrosis of lymph nodes or the adjacent lymphatics.² This often presents as hydrocele (in men), massive lymphoedema and elephantiasis. It is common in tropical and sub-tropical regions of Africa, the Far East and South America. Another common cause in the tropics is podoconiosis (endemic non-filarial elephantiasis), a geochemical disease that occurs in individuals exposed to red clay soil derived from alkalic volcanic rock.³ Ultra fine silica particles are absorbed through the skin of barefoot agricultural workers and cause a progressive obliterative lymphangitis.

In Europe and North America secondary lymphoedema is usually related to trauma, surgery, and radiotherapy, often associated with the treatment of malignancy.

Classification of primary lymphoedema

The original classification of primary lymphoedema according to age of onset

into congenital (present at birth), praecox (appearing before 35 years of age) and tarda is of little use in differentiating the underlying disease processes. In the 1950s Kinmonth proposed both the clinical distinction of primary and secondary lymphoedema and a classification system based on lymphangiographic appearance.⁴ Browse later combined these into a system that reflected clinical and aetiological factors known at the time.⁵

- 1) Primary lymphoedema: Lymphoedema caused by a primary abnormality or disease of the lymph conducting elements of the lymph vessels or lymph nodes. Those in which the functional abnormality and its cause are known are divided into three groups:
 - a. large vessel abnormalities such as congenital aplasia of the thoracic duct or cysterna chyli
 - b. congenital lymphatic valvular incompetence or congenital aplasia
 - c. lymph node fibrosis.

TABLE 27.1:

Secondary causes of swelling that must be excluded before making a diagnosis of lymphoedema
Cardiac failure
Renal failure
Hepatic failure
Hypoproteinaemia
Allergic disorders
Vasculitis
Hereditary angio-oedema
Idiopathic cyclic oedema
Venous insufficiency (Obstruction or reflux)
Vascular malformations
Lipoedema / lipodystrophy
Functional (disuse)
Factitious
Gigantism (overgrowth syndromes)
Investigations to exclude other causes of swelling
ECG
Echocardiography
FBC
U+E / Creatinine
LFT including albumin
CRP / ESR
Autoimmune screen
Complement tests
Venous duplex
Contrast venography
MRI for soft tissue swelling / vascular malformation
CT abdomen and pelvis
Lymphoscintigraphy
Lymphography

The remainder are characterised by a reduced number of lymphatics on lymphography

- 2) Secondary lymphoedema: Oedema caused by disease in the nodes or vessels that began elsewhere (e.g., neoplasia or filariasis), or lymphocytic proliferative disorders such as Hodgkin's disease or following surgical extirpation of lymph nodes or vessels.

More recently genetic abnormalities have been discovered in both congenital (present at birth) and delayed onset forms of lymphoedema and this has led to a modified view of this classification. There is also a distinction between 'lymphangio-obstructive' and 'lymphangio-obliterative' to indicate underlying pathology.

- 1) Genetically determined abnormalities
 - a. Aplasia, malformation and valvular incompetence of the central lymphatic ducts, namely the cisterna chyli and thoracic duct
 - b. Aplasia, hypoplasia or dilatation and valvular incompetence of the collecting ducts in the subcutaneous tissues of the limb and trunk. This group therefore includes the familial conditions such as Milroy's, Meige's and lymphoedema-distichiasis syndromes. This group also includes sporadic congenital lymphoedema associated with some recognised congenital abnormalities. (Table 27.2).
- 2) Acquired abnormalities
 - a. Lymphangio-obliterative lymphoedema
 - i. Distal
 - ii. Proximal
 - iii. Combined
 - b. Intra-glandular (hilar) fibrosis; representing the lymphangio-obliterative process in the lymph conducting parts of the lymph gland

- 3) Kinmonth's numerical hyperplasia; the lymphangiographical abnormality is of increased numbers of normally sized lymphatic channels associated with excessive numbers of small lymph glands.

THE GENETICS OF LYMPHANGIOGENESIS IN PRIMARY LYMPHOEDEMA

Milroy's disease

Milroy first described a syndrome of inherited, painless, non-progressive swelling of the legs present at birth in 1892.⁶ The family genealogy of the affected clergyman was followed across six generations and 22 out of 97 descendants were thought to have limb swelling indicative of lymphoedema.

Milroy's disease is an autosomal dominantly inherited condition. Linkage studies have mapped the condition to a locus on chromosome 5q35.3. More than 30 mutations in vascular endothelial growth factor receptor-3 (VEGFR-3), which maps to this region, have now been identified.⁷⁻¹³ De novo mutations in the VEGFR-3 have also now been reported in patients with sporadic congenital lymphoedema.^{14,15}

VEGFR-3 is the receptor for VEGF-C and VEGF-D. VEGF-C acts through VEGFR-2 and VEGFR-3 during formation of the vascular system, with expression of VEGFR-3 becoming restricted to the lymphatic endothelium.^{16,17,18} The ability to specifically target lymphatic endothelium has allowed the visualisation of channels in mouse and human lymphatics with markers such as lymphatic vessel endothelial hyaluronan receptor (LYVE-1)¹⁹ (Figure 27.2).

TABLE 27.2:

Disorders and syndromes involving primary lymphoedema
Milroy disease
Lymphoedema-distichiasis syndrome
Hypotrichosis-lymphoedema-telangiectasia syndrome
Meige disease (Primary non-syndromic lymphoedema)
Lymphoedema and yellow nails
Lymphoedema with ptosis
Hennekam syndrome (Lymphoedema-lymphangiectasia-mental retardation)
Aagenaes syndrome (Hereditary intrahepatic cholestasis with lymphoedema)
Microcephaly-lymphoedema-chorioretinal dysplasia (MLCD)
Noonan syndrome
Turner syndrome (45, X karyotype)
Prader-Willi syndrome
Klippel-Trenaunay syndrome
Maffucci syndrome
Proteus syndrome

Transfection of adenoviral VEGF-C into the skin of mice causes massive dermal lymphangiogenesis,^{20,21,22} and transgenic expression of VEGF-C in mice increases lymphatic endothelial cell proliferation and causes lymphatic channel hyperplasia.²³ In contrast, targeted deletion of VEGFR-3 in mice causes defective vasculogenesis and embryonic death.²⁴ Transgenic mice expressing a soluble form of VEGFR-3 that is a potent inhibitor of VEGF-C and –D signaling survive into adulthood if a keratinocyte promoter is used to deliver the genetic mutation selectively to the dermis.²⁵ These animals have a normal blood vasculature but develop a lymphoedema phenotype with swollen limbs. These studies show that VEGFR-3 has an essential role in lymphangiogenesis. Further study of patients with Milroy's disease show that the lymphatics in the upper limb are completely normal, and in the lower limb they are present in the skin but there is no functional uptake.¹³

Lymphoedema-distichiasis syndrome

Lymphoedema-distichiasis syndrome is an autosomal dominantly inherited condition caused by mutations in the FOXC2 (forkhead transcription factor) gene at 16q24 locus.²⁶ Distichiasis described an extra growth of eyelashes from the Meibomian glands, and 30% also have ptosis. Distichiasis often causes corneal irritation, recurrent conjunctivitis and photophobia (Figure 27.3). It can be treated in a number a ways, including lubrication, plucking, electrolysis and surgery. The condition is associated with other congenital abnormalities including congenital heart defects (tetralogy of Fallot), cleft lip and palate, varicose veins and spinal extradural cysts.²⁷

In this condition distichiasis is present from birth and lymphoedema appears from puberty. It is often bilateral and is usually below the knee. Duplex ultrasound and lymphoscintigraphy reveal that patients have both lymph and venous reflux in lower




FIGURE 27.2: Human dermal tissue stained with marker for LYVE-1 expression on lymphatic endothelium




FIGURE 27.3: Distichiasis with accessory eyelashes along the posterior border of the lid margin in the position of the Meibomian glands

limbs, suggesting primary valve failure.²⁸ Skin biopsies in individuals with FOXC2 mutations demonstrate an abnormally large proportion of lymphatic vessels which are covered with smooth muscle cells, compared to family members without the mutation. Similar findings in FOXC2 knockout mice indicates that FOXC2 is both essential for valve morphogenesis as well as normal interactions between lymphatic endothelial cells and pericytes.²⁹ Venous reflux in lymphoedema-distichiasis syndrome could be a significant factor in the onset and progression of swelling.

Hypotrichosis-lymphoedema-telangiectasia syndrome

Hypotrichosis-lymphoedema-telangiectasia syndrome is caused by mutations in the transcription factor gene SOX18.³⁰ This extremely rare syndrome is characterized by the association of childhood-onset lymphoedema in the legs, loss of hair, and telangiectasia, particularly in the palms. Inheritance is either autosomal dominant or

autosomal recessive. Studies of the naturally occurring SOX18-mutant mouse strain suggest abnormal expression of a number of downstream gene targets required for structural integrity during microvascular maturation.³¹ SOX18 directly activates transcription of the Prox1 gene which controls lymphatic vessel development from endothelial precursor cells.³²

Meige disease (primary non-syndromic lymphoedema)

In 1898, Henri Meige described the most common variety of primary lymphoedema.³³ Meige disease is a familial lymphoedema developing at or soon after puberty in which no other congenital abnormality is identified. The lymphoedema is often symmetrical, rarely extends above the knee, and is clinically indistinguishable from that found in lymphoedema-distichiasis syndrome. It occurs three times more commonly in females than males and has a genetic predisposition in about a third of cases. Lymphography demonstrates peripheral

lymphatic hypoplasia with more proximal lymphatic channels remaining patent. The genetic abnormality in this syndrome has not been discovered but it has been shown not to involve the FOXC2 gene.³⁴

Other primary lymphoedema disorders

Two other very rare forms of primary lymphoedema have been proposed to exist; lymphoedema associated with discoloured, slow growing and excessively curved nails (lymphoedema and yellow nail syndrome), and lymphoedema with ptosis. These may both represent poorly phenotyped cases rather than truly exist as separate entities, as yellow nails can be found in Milroy's disease, Meige disease and lymphoedema-distichiasis, and ptosis occurs in lymphoedema-distichiasis.³³

Many other syndromes are known to have lymphoedema as a clinical feature (Table 27.2). Lymphoedema may affect the whole body or can affect arms, legs, face, conjunctiva, and the genitalia in a segmental pattern. In primary lymphoedema, facial, conjunctival or genital lymphoedema is often associated with limb involvement. Systemic disorders of the lymphatics include intestinal lymphangiectasia, chylous ascites, pleural effusions, pericardial effusions and pulmonary lymphangiectasia. The surgical treatment of these disorders is complex and may involve ligation or excision of refluxing lymphatics, or drainage procedures.

STRUCTURE AND DEVELOPMENT OF THE LYMPHATIC CIRCULATION

The lymphatic system consists of a vascular network of thin-walled, blind ended capillaries made up of a single-cell layer of endothelial cells joined by discontinuous button-like junctions that open in response

to increased interstitial fluid pressure.³⁵ Lymphatic capillaries have no basement membrane or supporting smooth muscle cells or pericytes, and so are highly permeable to protein-rich lymph fluid. They do, however, possess specialised anchoring filaments that link the endothelial cells to surrounding matrix and tissues; these help keep the capillaries open and increase their permeability as interstitial pressure rises.³⁶⁻³⁸ The lymphatic capillaries converge into precollecting lymphatic vessels and these carry lymph to the main collecting trunks (e.g. the thoracic duct) for return to the venous circulation. Unlike lymphatic capillaries, precollecting and collecting trunks contain smooth muscle cells and pericytes. Collecting lymphatics also have internal valves to prevent retrograde flow of lymph fluid.

Early research into the origin of the lymphatics relied on either injection of substances (dyes or resins) into the circulation or serial sectioning to visualise early lymphatic vessel and sac development. This resulted in two opposing models: the first proposed by anatomists and embryologists using injection techniques that the lymphatic vessels bud off the primitive veins and grow out by lymphangiogenesis;³⁹ and the second that lymphatic vessels arise from the mesenchymal spaces with lymphatic sacs coalescing to form vessels.⁴⁰

More recently molecular techniques have better characterised the origin of lymphatics in several models.⁴¹ Studies using VEGFR-3 expression as a marker of lymphatic endothelial cells (LECs) in an avian model have suggested a dual origin from mesodermal lymphangioblasts and adjacent veins⁴² and similar conclusions have been drawn in an amphibian model examining staged expression of the prospero-related homeobox gene, Prox1.⁴³ A number of other studies, both in mice and a zebrafish model, have concluded

that the majority of cells contributing to LEC arise from primitive veins. If there is a haematopoietic contribution to LEC this occurs relatively late and peripherally in their development, and may also contribute to postnatal physiological or pathological lymphangiogenesis.

The homeobox transcription factor, *Prox1* is required for lymphatic cell differentiation. *Prox1* is exclusively expressed in a subpopulation of endothelial cells in the anterior cardinal vein that emerge from the vein and form lymph sacs.⁴⁴ *Prox1* knockout mouse embryos do not develop lymphatic vessels⁴⁴ with the budding embryonic venous endothelial cells defaulting to a blood vascular rather than lymphatic phenotype.⁴⁵ Lineage tracing studies have provided further evidence that LECs sprout, proliferate and migrate from venous-derived lymph sacs and haematopoietic cells do not contribute to the mammalian lymphatic system.⁴⁶ Temporal inactivation of *Prox1* during embryonic and postnatal lymphangiogenesis causes loss of LEC phenotype and reversion to a blood vessel endothelial phenotype.⁴⁷

Recent studies suggest that the transcription factor *SOX18* controls *Prox1* expression. Mutations in *SOX18* were identified in patients with hypotrichosis-lymphoedema-telangiectasia syndrome.³⁰ *SOX18* directly controls *Prox1* expression by binding to its promoter; *SOX18* knockout mice do not express *Prox1* in cardinal vein endothelial cells and develop gross oedema.³²

Further proliferation and migration of LECs from embryonic veins is controlled by *VEGFR-3*. Initially expressed in both blood and LECs, expression becomes restricted during embryogenesis. As discussed above, mutations in *VEGFR-3* cause Milroy's disease in humans. *VEGFC* is the principal ligand of *VEGFR-3*; in *VEGFC* knockout mice LECs are correctly specified, as defined by the normal expression of *LYVE-1*,

Prox1 and *VEGFR-3*, but fail to proliferate and migrate.²¹ *Neuropilin-2* is a non-signalling transmembrane receptor that acts as a co-receptor for *VEGFR-3*; *Neuropilin-2* knockout mice have lymphatic hypoplasia with normal development of arterial and venous vasculature.⁴⁸ The transcription factor *Tbx1* activates *VEGFR-3* expression in endothelial cells and is the major gene for DiGeorge syndrome in humans. *Tbx1* does not seem to be required for LEC differentiation but is needed for further growth and maintenance of lymphatic vessels; deletions in the gene cause widespread disruption of lymphangiogenesis.⁴⁹

A number of other genes have been implicated in further lymphatic maturation and remodelling. Mutations in the forkhead transcription factor *FOXC2* have been found in patients with lymphoedema-distichiasis syndrome, as discussed above. Lymphatic vessels are correctly differentiated in *FOXC2* knockout mice⁵⁰ but there is abnormal recruitment of smooth muscle cells to lymphatic capillaries as well as agenesis of lymphatic valves.²⁹ Recently *FOXC2* has been shown to play an important role in the formation of mature lymphatic collectors, including the formation of valves, recruitment of mural cells and smooth muscle, and pruning of branches.⁵¹ In addition the transcription factor *NFATc1* interacts with *FOXC2* binding enhancers during valve formation.

Many other genes that have been implicated in abnormal lymphatic maturation including *Angiopoietin-2*,⁵² *EphrinB2*, *Aspp51*, *Emilin1*, *Slp76* and *Syk*.⁴¹ For example *Ang-2* knockout mice have subcutaneous oedema and chylous ascites; their lymphatics have a disorganised appearance, with poorly developed and disorganised circumferential smooth muscle coat. The relationship between these genes and human conditions has yet to be defined. Platelets may also play

a role in separating blood and lymphatic vessels during embryogenesis.⁵³ Understanding the mechanisms of lymphangiogenesis may lead to pro-lymphangiogenic treatments for lymphoedema.⁵⁴

CLINICAL ASPECTS OF LYMPHOEDEMA

Most patients present with unilateral leg swelling. At an early stage the swelling will easily pit if pressure is applied, but chronic lymphoedema is associated with fibrosis and the subcutaneous tissues become thickened and hard. At a microscopic level the perilymphatic space becomes chronically thickened with a granulofilamentous material containing degenerate elastic fibres and collagen. In the presence of poorly functioning lymphatics, interstitial fluid becomes stagnant and can become infected; sometimes an infection may be an initial event and the subsequent swelling is blamed on this, but it is more likely to be a consequence of pre-existing abnormal lymphatic drainage. *Streptococcus pyogenes* is the most common pathogen. Patients may present with recurrent episodes of cellulitis, and each episode of infection predisposes to fibrosis and further lymphatic damage. Acute inflammation induces hyperaemia and increased hydrostatic pressure as well as increased vascular permeability and so increases accumulation of protein rich interstitial fluid. Endothelial derived nitrous oxide and oxygen free radicals are released; these are vasodilators and also inhibit the spontaneous tonic and phasic contractions of the lymphatic vessel wall smooth muscle, further reducing lymphatic flow.

Inguinal lymph nodes may be enlarged, especially if there is pelvic obstruction. Cutaneous lymphatic vesicles or a capillary naevus are signs of underlying megalymphatics with reflux. Release of cytokines causes thickening

of dermal keratinocytes and an acanthotic appearance of the dermis. Inflammatory cells migrate from the papillary dermal layers into the epidermal cell layer. Microfilament deposition in the dermo-epidermal junction leads to a thickened epidermal basal lamina. This hyperplasia and hypertrophy of the dermal vascular endothelial and epidermal cells is responsible for the abnormal papillomatosis that develops in the skin of many patients with chronic lymphoedema.

Patients with megalymphatics may have chylous ascites, chyluria, chylometrorrhoea, chylothorax or other manifestations of lymphatic fistulae.

SUMMARY

Primary lymphoedema and other syndromes associated with lymphoedema cause significant morbidity. Molecular techniques have greatly improved our understanding of lymphatic specification, lymphangiogenesis, and lymphatic maturation. The relevance of genetic abnormalities in the development of different types of primary lymphoedema is now being elucidated. Increased understanding of these mechanisms will increase the number of candidate genes for genetic testing in both idiopathic inherited and sporadic forms of lymphoedema. Understanding of each of these processes will eventually lead to more effective treatments for disorders of the lymphatic system.

REFERENCES


1. Dale RF. The inheritance of primary lymphoedema. *J Med Genet* 1985 Aug; **22**(4): 274–8.
2. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. *Lancet* 2010 Oct 2; **376**(9747): 1175–85.

3. Fuller LC. Podoconiosis: endemic nonfilarial elephantiasis. *Curr Opin Infect Dis* 2005 Apr; **18**(2): 119–22.
4. Kinmonth JB. Lymphangiography in man; a method of outlining lymphatic trunks at operation. *Clin Sci (Lond)* 1952 Feb; **11**(1):13–20.
5. Browse NL, Stewart G. Lymphoedema: pathophysiology and classification. *J Cardiovasc Surg (Torino)* 1985 Mar–Apr; **26**(2): 91–106.
6. Milroy, W.F. 1892. An undescribed variety of hereditary edema. *NY Med J* **56**: 503.
7. Ferrell RE, Levinson KL, Esmen JH, Kimak MA, Lawrence EC, Barmada MM, Finegold DN. Hereditary lymphedema: evidence for linkage and genetic heterogeneity. *Hum Mol Genet* 1998 Dec; **7**(13): 2073–8.
8. Evans AL, Brice G, Sotirova V, Mortimer P, Beninson J, Burnand K, Rosbotham J, Child A, Sarfarazi M. Mapping of primary congenital lymphedema to the 5q35.3 region. *Am J Hum Genet* 1999 Feb; **64**(2):547–55.
9. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. *Nat Genet* 2000 Jun; **25**(2): 153–9.
10. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. *Am J Hum Genet* 2000 Aug; **67**(2): 295–301.
11. Evans AL, Bell R, Brice G, Comeglio P, Lipede C, Jeffery S, Mortimer P, Sarfarazi M, Child AH. Identification of eight novel VEGFR-3 mutations in families with primary congenital lymphoedema. *J Med Genet* 2003 Sep; **40**(9): 697–703.
12. Butler MG, Dagenais SL, Rockson SG, Glover TW. A novel VEGFR3 mutation causes Milroy disease. *Am J Med Genet A* 2007 Jun 1; **143A**(11): 1212–7.
13. Connell F, Brice G, Mortimer P. Phenotypic characterization of primary lymphedema. *Ann NY Acad Sci* 2008; **1131**: 140–6.
14. Ghalamkarpour A, Morlot S, Raas-Rothschild A, Utkus A, Mulliken JB, Boon LM, Vikkula M. Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. *Clin Genet* 2006 Oct; **70**(4): 330–5.
15. Carver C, Brice G, Mansour S, Ostergaard P, Mortimer P, Jeffery S; Lymphoedema Consortium. Three children with Milroy disease and de novo mutations in VEGFR3. *Clin Genet* 2007 Feb; **71**(2): 187–9.
16. Hamada K, Oike Y, Takakura N, Ito Y, Jussila L, Dumont DJ, Alitalo K, Suda T. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. *Blood* 2000 Dec 1; **96**(12): 3793–800.
17. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. *Proc Natl Acad Sci USA* 1995 Apr 11; **92**(8): 3566–70.
18. Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine

- kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). *Proc Natl Acad Sci USA* 1998 Jan 20; **95**(2): 548–53.
19. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. *J Cell Biol* 1999 Feb 22; **144**(4): 789–801.
 20. Enholm B, Karpanen T, Jeltsch M, Kubo H, Stenback F, Prevo R, Jackson DG, Ylä-Herttuala S, Alitalo K. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. *Circ Res* 2001 Mar 30; **88**(6): 623–9. Erratum in: *Circ Res* 2001 Jul 6; **89**(1): E15.
 21. Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, Bueler H, Eichmann A, Kauppinen R, Kettunen MI, Ylä-Herttuala S, Finegold DN, Ferrell RE, Alitalo K. A model for gene therapy of human hereditary lymphedema. *Proc Natl Acad Sci USA* 2001 Oct 23; **98**(22): 12677–82.
 22. Saaristo A, Veikkola T, Enholm B, Hytönen M, Arola J, Pajusola K, Turunen P, Jeltsch M, Karkkainen MJ, Kerjaschki D, Bueler H, Ylä-Herttuala S, Alitalo K. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. *FASEB J* 2002 Jul; **16**(9): 1041–9.
 23. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. *Science* 1997 May 30; **276**(5317): 1423–5. Erratum in: *Science* 1997 Jul 25; **277**(5325): 463.
 24. Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, Breitman M, Alitalo K. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. *Science* 1998 Oct 30; **282**(5390): 946–9.
 25. Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S, Ylä-Herttuala S, Alitalo K. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. *Nat Med* 2001 Feb; **7**(2): 199–205.
 26. Fang J, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, Gorski JL, Seaver LH, Glover TW. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. *Am J Hum Genet* 2000 Dec; **67**(6): 1382–8.
 27. Brice G, Mansour S, Bell R, Collin JR, Child AH, Brady AF, Sarfarazi M, Burnand KG, Jeffery S, Mortimer P, Murday VA. Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. *J Med Genet* 2002 Jul; **39**(7): 478–83.
 28. Mellor RH, Brice G, Stanton AW, French J, Smith A, Jeffery S, Levick JR, Burnand KG, Mortimer PS; Lymphoedema Research Consortium. Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb. *Circulation* 2007 Apr 10; **115**(14): 1912–20.
 29. Petrova TV, Karpanen T, Norrmén C, Mellor R, Tamakoshi T, Finegold D, Ferrell R, Kerjaschki D, Mortimer P,

- Ylä-Herttua S, Miura N, Alitalo K. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. *Nat Med* 2004 Sep; **10**(9): 974–81. PMID: 15322537.
30. Irrthum A, Devriendt K, Chitayat D, Matthijs G, Glade C, Steijlen PM, Fryns JP, Van Steensel MA, Vikkula M. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. *Am J Hum Genet* 2003 Jun; **72**(6): 1470–8.
 31. Downes M, François M, Ferguson C, Parton RG, Koopman P. Vascular defects in a mouse model of hypotrichosis-lymphedema-telangiectasia syndrome indicate a role for SOX18 in blood vessel maturation. *Hum Mol Genet* 2009 Aug 1; **18**(15): 2839–50.
 32. Francois M, Caprini A, Hosking B, et al. Sox18 induces development of the lymphatic vasculature in mice. *Nature* 2008; **456**(7222): 643–647.
 33. Meige H. Dystrophe oedemateuse hereditaire. *Presse Medicale* 1898; **(6)**: 341–343.
 34. Rezaie T, Ghoroghchian R, Bell R, Brice G, Hasan A, Burnand K, Vernon S, Mansour S, Mortimer P, Jeffery S, Child A, Sarfarazi M. Primary non-syndromic lymphoedema (Meige disease) is not caused by mutations in FOXC2. *Eur J Hum Genet* 2008 Mar; **16**(3): 300–4.
 35. Baluk P, Fuxe J, Hashizume H, et al. 2007. Functionally specialized junctions between endothelial cells of lymphatic vessels. *J Exp Med* **204**: 2349–2362.
 36. Leak LV, Burke JF. 1966. Fine structure of the lymphatic capillary and the adjoining connective tissue area. *Am J Anat* **118**: 785–809.
 37. Gerli R, Ibba L, Fruschelli C. 1990. A fibrillar elastic apparatus around human lymph capillaries. *Anat Embryol* **181**: 281–286.
 38. Rossi A, Weber E, Sacchi G, Maestrini D, Di Cintio F, Gerli R. Mechanotransduction in lymphatic endothelial cells. *Lymphology* 2007 Sep; **40**(3): 102–13.
 39. Sabin F. 1902. On the origin of the lymphatic system from the veins, and the development of the lymph hearts and thoracic duct in the pig. *Am J Anat* **1**: 367–389.
 40. Huntington G, McClure C. 1910. The anatomy and development of the jugular lymph sac in the domestic cat (*Felis domestica*). *Am J Anat* **10**: 177–311.
 41. Butler MG, Isogai S, Weinstein BM. Lymphatic development. *Birth Defects Res C Embryo Today* 2009 Sep; **87**(3): 222–31.
 42. Wilting J, Aref Y, Huang R, Tomarev SI, Schweigerer L, Christ B, Valasek P, Papoutsi M. Dual origin of avian lymphatics. *Dev Biol* 2006 Apr 1; **292**(1): 165–73.
 43. Ny A, Koch M, Schneider M, Neven E, Tong RT, Maity S, Fischer C, Plaisance S, Lambrechts D, Héligon C, Terclavers S, Ciesiolka M, Kälin R, Man WY, Senn I, Wyns S, Lupu F, Brändli A, Vleminckx K, Collen D, Dewerchin M, Conway EM, Moons L, Jain RK, Carmeliet P. A genetic *Xenopus laevis* tadpole model to study lymphangiogenesis. *Nat Med* 2005 Sep; **11**(9): 998–1004.
 44. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. *Cell* 1999 Sep 17; **98**(6): 769–78.
 45. Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn MD,

- Jackson DG, Oliver G. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. *EMBO J* 2002 Apr 2; **21**(7): 1505–13.
46. Srinivasan RS, Dillard ME, Lagutin OV, Lin FJ, Tsai S, Tsai MJ, Samokhvalov IM, Oliver G. Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. *Genes Dev* 2007 Oct 1; **21**(19): 2422–32.
47. Johnson NC, Dillard ME, Baluk P, McDonald DM, Harvey NL, Frase SL, Oliver G. Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity. *Genes Dev* 2008 Dec 1; **22**(23): 3282–91.
48. Yuan L, Moyon D, Pardanaud L, Bréant C, Karkkainen MJ, Alitalo K, Eichmann A. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. *Development* 2002 Oct; **129**(20): 4797–806.
49. Chen L, Mupo A, Huynh T, Cioffi S, Woods M, Jin C, McKeenan W, Thompson-Snipes L, Baldini A, Illingworth E. Tbx1 regulates Vegfr3 and is required for lymphatic vessel development. *J Cell Biol* 2010 May 3; **189**(3): 417–24.
50. Dagenais SL, Hartsough RL, Erickson RP, Witte MH, Butler MG, Glover TW. Foxc2 is expressed in developing lymphatic vessels and other tissues associated with lymphedema-distichiasis syndrome. *Gene Expr Patterns* 2004 Oct; **4**(6): 611–9.
51. Norrmén C, Ivanov KI, Cheng J, Zangger N, Delorenzi M, Jaquet M, Miura N, Puolakkainen P, Horsley V, Hu J, Augustin HG, Ylä-Herttuala S, Alitalo K, Petrova TV. FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. *J Cell Biol* 2009 May 4; **185**(3): 439–57.
52. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D, Suri C, Campochiaro PA, Wiegand SJ, Yancopoulos GD. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. *Dev Cell* 2002 Sep; **3**(3): 411–23.
53. Bertozzi CC, Hess PR, Kahn ML. Platelets: covert regulators of lymphatic development. *Arterioscler Thromb Vasc Biol* 2010 Dec; **30**(12): 2368–71.
54. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. *Curr Opin Cell Biol* 2009 Apr; **21**(2): 154–65.



Cover diagram by David Heinrich of the Medical Illustration and Media Unit, Flinders Medical Centre. (See chapter 18)

MECHANISMS OF VASCULAR DISEASE

Edited by Robert Fitridge and Matthew Thompson

Chapter 1: Endothelium **Chapter 2:** Vascular smooth muscle structure and function **Chapter 3:** Atherosclerosis **Chapter 4:** Mechanisms of plaque rupture **Chapter 5:** Current and emerging therapies in atheroprotection **Chapter 6:** Molecular approaches to revascularisation in peripheral vascular disease **Chapter 7:** Biology of restenosis and targets for intervention **Chapter 8:** Vascular arterial haemodynamics **Chapter 9:** Physiological haemostasis **Chapter 10:** Hypercoagulable states **Chapter 11:** Platelets in the pathogenesis of vascular disease and their role as a therapeutic target **Chapter 12:** Pathogenesis of aortic aneurysms **Chapter 13:** Pharmacological treatment of aneurysms **Chapter 14:** Aortic dissection and connective tissue disorders **Chapter 15:** Biomarkers in vascular disease **Chapter 16:** Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon **Chapter 17:** SIRS, sepsis and multiorgan failure **Chapter 18:** Pathophysiology of reperfusion injury **Chapter 19:** Compartment syndrome **Chapter 20:** Pathophysiology of pain **Chapter 21:** Postamputation pain **Chapter 22:** Treatment of neuropathic pain **Chapter 23:** Principles of wound healing **Chapter 24:** Pathophysiology and principles of varicose veins **Chapter 25:** Chronic venous insufficiency and leg ulceration: Principles and vascular biology **Chapter 26:** Pathophysiology and principles of management of the diabetic foot **Chapter 27:** Lymphoedema – Principles, genetics and pathophysiology **Chapter 28:** Graft materials past and future **Chapter 29:** Pathophysiology of vascular graft infections



BARR SMITH PRESS

An imprint of
The University of Adelaide Press